Cargando…
Universal Access to HIV Treatment versus Universal ‘Test and Treat’: Transmission, Drug Resistance & Treatment Costs
In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ∼1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal ‘test and treat’ (T&T) strategy to try to eliminate HI...
Autores principales: | Wagner, Bradley G., Blower, Sally |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434222/ https://www.ncbi.nlm.nih.gov/pubmed/22957012 http://dx.doi.org/10.1371/journal.pone.0041212 |
Ejemplares similares
-
Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks
por: Wagner, Bradley G., et al.
Publicado: (2012) -
Cost-effectiveness of universal HIV testing and treatment: where
next?
por: Nachega, Jean B, et al.
Publicado: (2021) -
How can we achieve universal access to low-cost treatment for HIV?
por: Hill, Andrew M, et al.
Publicado: (2016) -
Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia
por: Hoare, Alexander, et al.
Publicado: (2010) -
Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment
por: Nunn, Amy S, et al.
Publicado: (2007)